☆ 4.6 Article

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors

ANNALS OF MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL

Tanya Siddiqi et al.

Summary: Lisocabtagene maraleucel, an autologous CD19-directed CAR T-cell therapy, shows promising safety and efficacy in patients with relapsed/refractory CLL/SLL, providing a potential new treatment option for these patients who develop resistance to current therapies.

BLOOD (2022)

Add to Collection

Review Oncology

Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis

Wenjing Luo et al.

Summary: This review systematically analyzes the hematologic toxicity in hematologic malignancies treated with CAR-T cell therapy. The most common side effect is hematological toxicity, with neutropenia, thrombocytopenia and anemia being the most common adverse events. Younger patients, those with more treatment lines, and patients with CD19-positive malignancies are more likely to experience hematological toxicity.

BMC CANCER (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

CD19 or CD20 CAR T Cell Therapy Demonstrates Durable Antitumor Efficacy in Patients with Central Nervous System Lymphoma

Rui Liu et al.

Summary: This study evaluated the clinical efficacy of CD19 or CD20 CAR T cell therapy for patients with central nervous system lymphoma. The results showed that CAR T cell therapy was effective and resulted in complete remission in some patients. The median duration of remission was 22.4 months. Combination therapy and early CAR T cell therapy after relapse may contribute to long-term remission.

HUMAN GENE THERAPY (2022)

Add to Collection

Article Oncology

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma

Koji Kato et al.

Summary: The study confirmed the efficacy and safety of axi-cel in Japanese patients with relapsed/refractory large B-cell lymphoma, providing a potential treatment option for this patient population.

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Aging and Clonal Behavior of Hematopoietic Stem Cells

Masayuki Yamashita et al.

Summary: This review summarizes the changes in hematopoietic stem cells (HSCs) during aging and how different clones of HSCs can be expanded. Research shows that in mice and humans, the clonal behavior of HSCs is closely related to the risk of hematological malignancies and cardiovascular diseases. Therefore, understanding the impact of aging on the hematopoietic system is critical to prevent or overcome age-related changes in the blood.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Oncology

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Caron A. Jacobson et al.

Summary: This study assessed the use of axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma and found that it showed high rates of durable responses and had a manageable safety profile.

LANCET ONCOLOGY (2022)

Add to Collection

Article Oncology

Evaluation of the safety and efficacy of humanized anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed/refractory diffuse large B-cell lymphoma based on the comprehensive geriatric assessment system

Huan Zhang et al.

Summary: In elderly patients with R/R DLBCL receiving anti-CD19 CAR T-cell therapy, stratification based on comprehensive geriatric assessment (CGA) can effectively predict treatment response and adverse events.

LEUKEMIA & LYMPHOMA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

Nathan Hale Fowler et al.

Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.

NATURE MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Oncology

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients

Lei Fan et al.

Summary: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cell malignancies. A phase I dose-escalation study evaluating T cells transduced with CBM.CD19 CAR for the treatment of patients with refractory DLBCL demonstrated a 20% overall response rate at 4 weeks and a 50% response rate at 12 weeks post-infusion. Adverse events were observed in all patients, with a high incidence of cytokine release syndrome but no neurotoxicity or dose-limiting toxicities noted.

FRONTIERS OF MEDICINE (2022)

Add to Collection

Article Hematology

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Jordan Gauthier et al.

Summary: The type of CD19 CAR T-cell product independently affects the toxicity and efficacy in patients with relapsed or refractory aggressive B-NHL.

BLOOD (2022)

Add to Collection

Article Oncology

Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma

Ying Wang et al.

Summary: The combination of anti-BCMA and anti-CD19 CAR T cells has shown durable response in patients with relapsed or refractory MM, with manageable long-term safety profile. The overall response rate was 92%, and complete response or better was observed in 60% of patients. Adverse events mainly included cytokine release syndrome and neurotoxic events.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial

Yajing Zhang et al.

Summary: A clinical trial of CAR T cell therapy for recurrent/refractory non-Hodgkin lymphoma showed a high overall response rate and progression-free survival, with manageable side effects such as cytokine release syndrome and CAR T cell-related encephalopathy syndrome.

LEUKEMIA (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

Sattva S. Neelapu et al.

Summary: In a phase 2 trial, axicabtagene ciloleucel demonstrated high complete response rate and manageable safety profile as first-line treatment for high-risk large B-cell lymphoma.

NATURE MEDICINE (2022)

Add to Collection

Review Oncology

Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion

Leila Amini et al.

Summary: Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for certain hematological cancers. Successful CAR-T cell infusion requires timely preparation and consideration of various factors. This review provides a summary of the considerations in preparing patients for CAR-T cell therapy and highlights current limitations and future research areas.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

Add to Collection

Article Hematology

Preferential expansion of CD8+CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL

Aimee C. Talleur et al.

Summary: CD19-specific CAR T cells have potent antileukemia activity in pediatric and adult B-ALL patients, but not all patients achieve a complete response. This clinical study evaluated a new CD19-CAR T cell product in pediatric patients and showed that the treatment was safe and effective, with disease burden before infusion affecting the treatment outcome.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia

Saar Gill et al.

Summary: Adding autologous anti-CD19 humanized binding domain T cells (huCART-19) to ibrutinib treatment in patients with chronic lymphocytic leukemia (CLL) who did not achieve complete remission (CR) despite >= 6 months of ibrutinib resulted in high rates of deep and durable remissions.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

Jennifer M. Logue et al.

Summary: A retrospective study of 85 patients receiving axi-cel for LBCL found that prolonged cytopenias and infections were common post-treatment, with most patients experiencing recovery of these conditions over time. Infections within the first 30 days were associated with various factors, but no late deaths were attributed to infection.

HAEMATOLOGICA (2021)

Add to Collection

Review Oncology

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

M-L Schubert et al.

Summary: CAR T-cell therapy targeting CD19-expressing B cells has shown promising results in treating refractory and/or relapsed B-cell malignancies, but also presents challenges such as cytokine release syndrome and neurotoxicity syndrome. Optimal management strategies for the side-effects associated with CAR T-cell therapy are crucial as it expands into other diseases in hematology and oncology.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Biotechnology & Applied Microbiology

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies

Valentin Ortiz-Maldonado et al.

Summary: Evaluation of ARI-0001 cell administration in patients with relapsed/refractory CD19(+) malignancies showed significant efficacy in ALL patients, with low rates of neurotoxicity and procedure-related mortality.

MOLECULAR THERAPY (2021)

Add to Collection

Article Oncology

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial

Stephan Kadauke et al.

Summary: The study evaluated the effectiveness of risk-adapted preemptive tocilizumab treatment in preventing severe cytokine release syndrome after CTL019 therapy, showing a decrease in the expected incidence of grade 4 CRS without impacting the antitumor efficacy of CTL019.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Relmacabtagene autoleucel (relma-cel) CD19 CAR-T therapy for adults with heavily pretreated relapsed/refractory large B-cell lymphoma in China

Zhitao Ying et al.

Summary: The study of Relma-cel in patients with r/r LBCL in China demonstrated a high rate of durable responses and a low occurrence of CAR-T-associated toxicities, supporting its regulatory submission in the country.

CANCER MEDICINE (2021)

Add to Collection

Article Hematology

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma

John H. Baird et al.

Summary: CAR T-cell therapy targeting CD19 improves outcomes in LBCL treatment, but long-term monitoring of hematologic recovery, immune reconstitution, and antimicrobial prophylaxis is necessary for patients post-treatment.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies

Sarah J. Nagle et al.

Summary: CAR T-cell therapy is effective in treating patients with R/R DLBCL, but it is associated with significant prolonged hematologic toxicity (PHT) that can affect patients' survival rates. Risk factors associated with PHT include CRS, the use of tocilizumab or steroids, peak levels of ferritin and C-reactive protein. More research is needed to further investigate PHT and establish management standards.

AMERICAN JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Oncology

CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Yongxian Hu et al.

Summary: The study successfully developed CRISPR-edited universal CAR-T cells as a novel therapy for r/r ALL. Results showed that this therapy has a manageable safety profile and prominent antileukemia activity, providing an alternative treatment option for patients.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial

Shaun Cordoba et al.

Summary: Bicistronic CAR T cells targeting CD19 and CD22 (AUTO3) show clinical activity and low toxicity in patients with B cell acute lymphoblastic leukemia, but relapses may be due to limited CAR T cell persistence, highlighting the need to improve CAR T cell persistence for better efficacy.

NATURE MEDICINE (2021)

Add to Collection

Review Oncology

Immunogenicity of CAR T cells in cancer therapy

Dimitrios L. Wagner et al.

Summary: CAR T cells have shown significant clinical responses in patients with certain advanced-stage B cell malignancies, but some patients may experience anti-CAR immune responses leading to treatment failure. Strategies to monitor and reduce the risks of anti-CAR immune responses are needed to improve CAR T cell therapy outcomes.

NATURE REVIEWS CLINICAL ONCOLOGY (2021)

Add to Collection

Article Multidisciplinary Sciences

Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients

Michael Maschan et al.

Summary: Strategies to address challenges in product manufacturing can improve CAR-T cell therapies. Clinical trials using place-of-care manufacturing for CD19-directed CAR-T cells have shown low production failure rates and high remission rates in B-cell malignancy patients. Developing anti-CD19 CAR19 with specific domains has shown efficacy in treating patients with B-cell malignancies, with consistent results at multiple manufacturing sites.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Hematology

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

Bijal D. Shah et al.

Summary: The ZUMA-3 study evaluated the efficacy and safety of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The treatment showed a high response rate and tolerable safety profile, with revised adverse event management strategies helping to optimize the risk-benefit ratio.

BLOOD (2021)

Add to Collection

Article Oncology

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience

Andrew Schaefer et al.

Summary: Patients with relapsed/refractory DLBCL have poor outcomes, but CD19 CAR-T therapy has shown improved survival outcomes. Our study found a correlation between prolonged cytopenias post-CAR-T therapy and better progression-free and overall survival, but no association with cytokine release syndrome or neurotoxicity was observed.

CANCER MANAGEMENT AND RESEARCH (2021)

Add to Collection

Review Biochemistry & Molecular Biology

CAR T-Cell Therapy in Hematological Malignancies

Theresa Haslauer et al.

Summary: CAR T-cells are a promising therapeutic approach for hematological malignancies, particularly in lymphoma and acute lymphocytic leukemia. Despite encouraging clinical results, challenges remain in treating other hematological malignancies.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

Regina M. Myers et al.

Summary: In this study, huCART19 demonstrated high overall response rates in children and young adults with relapsed or refractory B-ALL, reaching 98% in the CAR-naive cohort and 100% in B-ALL patients. Despite common adverse events such as neurologic toxicities and cytokine release syndrome, these were mostly fully resolved, indicating durable remissions with long-term persistence achieved by huCART19.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Claire Roddie et al.

Summary: A novel second-generation CD19-CAR therapy (AUT01) has shown promising results in the treatment of relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL), demonstrating tolerable safety profile, high remission rates, and excellent persistence. This therapy has the potential to become a stand-alone treatment option for r/r adult B-ALL.

JOURNAL OF CLINICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

Bijal D. Shah et al.

Summary: KTE-X19 demonstrated a high rate of complete remission or complete remission with incomplete haematological recovery in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia. Median overall survival was not reached in responding patients, and the therapy showed a manageable safety profile. These findings suggest that KTE-X19 has the potential to provide long-term clinical benefit to these patients.

LANCET (2021)

Add to Collection

Article Biochemistry & Molecular Biology

CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial

Jay Y. Spiegel et al.

Summary: Despite impressive progress in CAR-T cell therapy, more than 50% of patients treated with CD19-targeting CAR-T cells experience disease progression, often associated with antigen loss. To address this issue, researchers tested a bispecific CAR targeting CD19 and/or CD22, which showed high efficacy in preventing relapse in patients with B-ALL and LBCL. Antigen loss was identified as a major cause of CAR T cell resistance, emphasizing the importance of engineering multi-specific CAR T cells with equivalent potency and cytokine production as a quality indicator for potency.

NATURE MEDICINE (2021)

Add to Collection

Article Oncology

A novel dominant-negative PD-1 armored anti-CD19 CAR T cell is safe and effective against refractory/relapsed B cell lymphoma

Xiaoqian Liu et al.

Summary: Refactory/relapsed B cell lymphoma patients treated with a novel dominant-negative PD-1 armored anti-CD19 CAR T cells showed 77.8% overall response rate and 55.6% complete response rate, with durable remissions in ongoing complete responders. The novel CD19-CAR T cell therapy was safe and effective, expanding and detectable in patients with ongoing complete response even at 12+ months post-infusion.

TRANSLATIONAL ONCOLOGY (2021)

Add to Collection

Review Virology

Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives

Roman P. Labbe et al.

Summary: Lentiviral vectors are crucial in the development of T cell therapies such as tisagenlecleucel, axicabtagene ciloleucel, and brexucabtagene autoleucel. However, obstacles remain in making these therapies widely available. The development of GMP-compliant technologies will play a key role in advancing lentiviral vector-engineered T cell therapies.

VIRUSES-BASEL (2021)

Add to Collection

Article Oncology

CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study

Guoqing Wei et al.

Summary: Dual-targeted CAR T cells against CD19 and CD22 show promising antilymphoma effects in patients with relapsed/refractory aggressive B-cell lymphoma, with high objective response and complete response rates. The study suggests that achieving complete response and receiving fewer lines of prior chemotherapy are independent prognostic factors associated with favorable progression-free survival.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Article Oncology

Novel two-chain structure utilizing KIRS2/DAP12 domain improves the safety and efficacy of CAR-T cells in adults with r/r B-ALL

Ming Sun et al.

Summary: A novel CAR structure based on KIRS2/Dap12 with 4-1BB co-stimulation domain showed enhanced anti-tumor efficacy and safety in adult patients with r/r B-ALL, leading to complete responses in all patients without neurotoxicity.

MOLECULAR THERAPY-ONCOLYTICS (2021)

Add to Collection

Article Oncology

A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Ying Zhang et al.

Summary: The study demonstrates the safety and potential clinical efficacy of bispecific CD19/22 CAR T cells in patients with R/R B-NHL, highlighting the importance of measuring kinetic parameters in predicting efficacy and safety in clinical applications of CAR T cell therapy.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk

Cuicui Lyu et al.

Summary: In refractory/relapsed diffuse large B-cell lymphoma patients, pretreatment with intensive debulking chemotherapy can improve the outcome of CAR-T therapy by enhancing short-term objective response rate and long-term overall survival, with outcomes comparable to those without high tumor bulk.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Review Oncology

Recent advances and discoveries in the mechanisms and functions of CAR T cells

Rebecca C. Larson et al.

Summary: This review summarizes the major advances that have been made in the efficacy and safety of CAR T cell therapies over the past 3 years and looks ahead to new findings that will impact the future of this immunotherapy.

NATURE REVIEWS CANCER (2021)

Add to Collection

Article Hematology

Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients

Ying Wang et al.

Summary: Immune reconstitution, especially humoral immunity, was prolonged in relapsed or refractory B cell acute lymphoblastic leukemia patients receiving anti-CD19 CAR-T cell therapy.

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)

Add to Collection

Article Hematology

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Na Wang et al.

BLOOD (2020)

Add to Collection

Article Hematology

Sequential CD19-22 CAR T therapy induces sustained remission in children with r/r B-ALL

Jing Pan et al.

BLOOD (2020)

Add to Collection

Article Oncology

Sustained Therapeutic Efficacy of Humanized Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Acute Lymphoblastic Leukemia

Gang Heng et al.

CLINICAL CANCER RESEARCH (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma

Jennifer N. Brudno et al.

NATURE MEDICINE (2020)

Add to Collection

Article Oncology

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia

Noelle Frey et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Commercialanti-CD19 CART cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center

Pierre Sesques et al.

AMERICAN JOURNAL OF HEMATOLOGY (2020)

Add to Collection

Article Oncology

Phase II trial of co-administration of CD19-and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma

Wei Sang et al.

CANCER MEDICINE (2020)

Add to Collection

Article Hematology

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

Chelsea C. Pinnix et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Hematology

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Tania Jain et al.

BLOOD ADVANCES (2020)

Add to Collection

Review Oncology

Recent advances in CAR-T cell engineering

Ruihao Huang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Oncology

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma

Kitsada Wudhikarn et al.

BLOOD CANCER JOURNAL (2020)

Add to Collection

Article Oncology

Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia

Runxia Gu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study

Jeremy S. Abramson et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Nirav N. Shah et al.

NATURE MEDICINE (2020)

Add to Collection

Article Immunology

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Xuan Zhou et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Immunology

A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma

Xinfeng Chen et al.

IMMUNOTHERAPY (2020)

Add to Collection

Article Biophysics

Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried et al.

BONE MARROW TRANSPLANTATION (2019)

Add to Collection

Review Oncology

Mechanisms of resistance to CAR T cell therapy

Nirali N. Shah et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies

Nirav N. Shah et al.

FRONTIERS IN ONCOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

A safe and potent anti-CD19 CAR T cell therapy

Zhitao Ying et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

Austin J. Sim et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)

Add to Collection

Article Oncology

Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Zi-Xun Yan et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR

Sara Ghorashian et al.

NATURE MEDICINE (2019)

Add to Collection

Article Oncology

Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma

Zhitao Ying et al.

MOLECULAR THERAPY-ONCOLYTICS (2019)

Add to Collection

Article Hematology

Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL

Kevin J. Curran et al.

BLOOD (2019)

Add to Collection

Article Oncology

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial

Frederick L. Locke et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, Research & Experimental

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

Mark B. Geyer et al.

JCI INSIGHT (2019)

Add to Collection

Article Biotechnology & Applied Microbiology

In Vivo Expansion and Antitumor Activity of Coinfused CD28-and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia

Zhi Cheng et al.

MOLECULAR THERAPY (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy

Mark B. Geyer et al.

MOLECULAR THERAPY (2018)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

Carlos A. Ramos et al.

MOLECULAR THERAPY (2018)

Add to Collection

Article Oncology

A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia

Gunilla Enblad et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Oncology

Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia

Yongxian Hu et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels

James N. Kochenderfer et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Biotechnology & Applied Microbiology

Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

Frederick L. Locke et al.

MOLECULAR THERAPY (2017)

Add to Collection

Article Medicine, General & Internal

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease

Jennifer N. Brudno et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

Add to Collection

Article Cell Biology

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells

Cameron J. Turtle et al.

SCIENCE TRANSLATIONAL MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

Daniel W. Lee et al.

LANCET (2015)

Add to Collection

Review Medicine, General & Internal

Smoking and the outcome of infection

R. Huttunen et al.

JOURNAL OF INTERNAL MEDICINE (2011)

Add to Collection

Article Surgery

Methodological index for non-randomized studies (MINORS):: Development and validation of a new instrument

K Slim et al.

ANZ JOURNAL OF SURGERY (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.